Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02530749 · ClinicalTrials.gov registry record
Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 265
- Enrollment target
NCT02530749: Completed study, sponsored by University of Colorado, Denver.
NCT02530749 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 265 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02530749 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 265 participants
- Enrollment target
Study Summary
Frailty as an adjunct to preoperative assessment of neurosurgical patients has never been evaluated. This study aims to determine if frailty predicts neurosurgical complications in brain tumor patients and enhances current perioperative risk models.
Primary Outcome
Number of patients with a complication risk based on a Hopkins Frailty Score (HFS).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-03 |
What the finished NCT02530749 record still lists
NCT02530749 is an observational study that tracks outcomes without assigning an intervention. The registered 265 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02530749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02530749 about?
NCT02530749 is a clinical study titled "Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients". Frailty as an adjunct to preoperative assessment of neurosurgical patients has never been evaluated. This study aims to determine if frailty predicts neurosurgical complications in brain tumor patients and enhances current perioperative risk models.
What is the current status of trial NCT02530749?
This trial is currently completed. The enrollment target is 265 participants. The study started on 2014-04. Estimated completion is 2019-03.
Who is sponsoring clinical trial NCT02530749?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05443126 · 265 participants · Phase 1
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
- NCT05470491 · 265 participants · Phase 1
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
- NCT07301905 · 265 participants · NA
Culturally Targeted Health Communication and Receptivity to the Human Papillomavirus Vaccine Among Parents in Flint, MI
- NCT07470853 · 265 participants · Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia